组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

老年人与“肾阳虚”患者的甲状腺轴功能对比观察

老年人的甲状腺组织萎缩,下丘脑—垂体—甲状腺轴功能降低。本文通过老年人以及同病种同年龄的肾阳虚型与无特殊见证型各10例的甲状腺功能对比,发现肾阳虚型患者的下丘脑—垂体—甲状腺轴功能似乎有提前衰老的表现。而温补肾阳法则可对此进行调节,改善甲状腺功能,具有延缓衰老,防治老年病的作用。现将研究过程陈述于下:     

多肽激素的酶促~(125)碘化及其保存稳定性研究(简报)

多肽激素的~(125)碘化标记对放射免疫分析、放射性受体分析、细胞膜抗原及免疫学研究均有重要意义。1963年Greenwood等创用氯胺T~(125)碘化法,国内外目前仍沿用,但氯胺T氧化作用较强,常使标记的多肽激素的生物活性和免疫活性受到损伤。七十年代中期国外学者进行乳过氧化物酶(Lactoproxidase,简称LPO)酶促~(125)碘化法,由于此法作用温和,故能使标记的多肽激素保持较好的生物及免疫活性,提高了标记激素的保存稳定性。我室在1972～1978年中应用氯胺T法~(125)碘化多肽激素实践的基础上,于1978～1981年起先后完成五种多肽激素的酶促~(125)碘化,并结合国内目前供应的~(125)碘     

~(131)碘治疗弥漫性甲状腺功能亢进远期并发甲状腺功能减退的临床及实验室观察

本文总结我院64例~(131)碘治疗弥漫性甲亢的随访结果,男性17例,女性47例,年龄从31～63岁。随访项目包括TT_4、TT_3、TSH、TRH兴奋试验、MCA、TGA、血清胆固醇、甘油三酯及ECG等。甲减的诊断及分型按Evered标准加以修改。远期甲减发病率:2～5年随访为25％,6～10年随访为50％,11～15年随访为58.8％,总的发病率为52.1％。甲减组和非甲减组甲状腺重量及接受~(131)碘的毫居里数未见统计差别;亚临床型甲减及轻型甲减之间除TT_3外,TT_4,TSH均值未见有意义差别。最后,作者就甲减的发病率、亚临床甲减的诊断和治疗、~(131)碘治疗弥漫性甲亢发生甲减的机理进行了讨论。     

糖类抗原CA50 TRFIA与IRMA对比分析

本文运用时间分辨荧光免疫分析（TRFIA）与免疫放射分析（IRMA）分别检测糖类抗原CAS0的含量,比较两种方法的相关性及各自的优势。     

胃泌素受体在胃癌中表达的意义

目的研究胃癌组织表达胃泌素受体（ＧＲ）的特征,是临床应用ＧＲ拮抗剂调控胃癌细胞生长的基础。方法应用受体的放射配基结合分析法测定３４例胃癌及癌旁胃粘膜组织ＧＲ含量及亲和力（Ｋｄ）。结果３４例胃癌组织中,１６例胃癌组织ＧＲ阳性,其中２例属低亲和力ＧＲ;１４例属高亲和力ＧＲ,计高含量ＧＲ９例（３９．５４±１４．４３ｆｍｏｌ／ｍｇ蛋白）和低含量ＧＲ５例（６．０３±２．８３ｆｍｏｌ／ｍｇ蛋白）。胃癌组织表达高含量ＧＲ的平均含量较癌旁胃粘膜组织高。胃体癌表达高亲和力ＧＲ的阳性率为７７．８％,胃底贲门癌为５０．０％,而胃窦癌为２１．１％。晚期胃癌表达高亲和力ＧＲ的阳性率为５２．２％,早、中期胃癌为１０．０％。结论４７．１％胃癌组织能表达ＧＲ;高亲和力、高含量ＧＲ在胃体癌、胃底贲门癌中表达的阳性率高;晚期胃癌表达的ＧＲ多属高亲和力。     

血清前列腺特异抗原免疫测定室间质控分析

通过回顾分析1998年5月～2002年2月我院室间的质量评估参数[变异指数得分值(VIS)和百分偏差值(BIS)]，评价本项目的质量，并对测定结果出现的偏差进行分析。     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.